

Press release

Vetter provides insights into its long-term expansion plans that include the purchasing of property in the City of Des Plaines

Ravensburg, Germany, July 15, 2016 – At a meeting held on July 12 for interested residents and other stakeholders, officials of the City of Des Plaines and Vetter were given the opportunity to share initial plans for the proposed purchase and development by Vetter of a 18 acre site, located at the corner of Mount Prospect and Algonquin Road. Vetter is a leading service provider for the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Its initial concept intends to offer its global customer base a US manufacturing opportunity for their market supply needs of commercialized drugs.

Vetter provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of injectable drugs. For this project, the company plans investments of approximately \$320 million on construction and site improvements over more than 10 years. Once it has reached its final expansion stage, the 18-acre site would include 1,138,237 SF of facility space. If approved, the facility would be the second US manufacturing site of the company. The Des Plaines project would complement its existing US clinical development support service offering which consists of a small-scale manufacturing facility located in the nearby Village of Skokie. Des Plaines would be the recipient of several positive outcomes including the creation of approximately 400-500 new jobs by the final expansion stage. Many of these are expected to be hired locally.

“We believe that this project represents a win-win scenario for the residents of Des Plaines and Vetter alike,” said Vetter Managing Director Peter Soelkner. “For us, it would be the next step in our plan for continuous growth. Several of our customers have requested commercial manufacturing resources both in US and Europe for their multi-faceted market production needs. Being in a continuous dialogue with them, such a facility would enlarge Vetter’s geographical manufacturing opportunities, and thus, increase our customer’s flexibility. We are excited about the positive outcomes this project can bring to the city of Des Plaines, and becoming a good and trustworthy neighbor to its residents. Des Plaines is a great partner in the process, we would be happy to receive the projects approval,” said Soelkner.

Founded as a modest pharmacy in Ravensburg, Germany, the company has grown from a local packager to a world-leading contract development and manufacturing organization, today serving the top 10 (bio-)pharmaceutical companies as well as small and midsize companies. If approved and realized, the facility would complement Vetter’s existing site at the Illinois Science+Technology Park in Skokie which has approximately 70 employees, most of whom are local residents. The purpose and scope of work between the two facilities would not be overlapping, but acting as a complementary service to its customers.



First view of Vetter's initial long-term plans in the city of Des Plaines.
Source: Vetter Pharma International GmbH

About Vetter

Vetter is a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with production facilities in Germany and the United States, the contract development and manufacturing organization (CDMO) is an innovative solution provider serving the top 10 (bio-)pharmaceutical companies, as well as small and midsize companies. Its portfolio spans state-of-the-art manufacturing from early clinical development through commercial filling and final packaging of parenteral drugs. The company's extensive experience covers a broad range of complex compounds including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company of approximately 3,600 employees offers a foundation of experience spanning more than 35 years, including dozens of customer product approvals for novel (bio-)pharmaceutical compounds. The CDMO is also committed to patient safety and compliance with user friendly solutions such as Vetter-Ject[®], as well as its dual-chamber syringe Vetter Lyo-Ject[®] and cartridge system V-LK[®]. Vetter's branch office in Singapore and its subsidiary in Tokyo, Japan, increase the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit www.vetter-pharma.com.

Contact

Vetter Pharma International GmbH
Oskar Gold
Senior Vice President Key Account Management,
Marketing / Corporate Communications
Eywiesenstrasse 5
88212 Ravensburg
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com